Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomomi Fujii

Showing results (51-60 of 159) with videos related to

Pageof 16
Sort By:
Journal of Contemporary Brachytherapy|November 22, 2019
Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancerYasushi Nakai, Nobumichi Tanaka, Isao Asakawa, et al.
Histopathology|October 10, 2023
Implication of cytoplasmic p53 expression in pulmonary neuroendocrine carcinoma using next-generation sequencing analysisNaoe Jimbo, Chiho Ohbayashi, Tomomi Fujii, et al.
The American Journal of Surgical Pathology|October 31, 2023
POU2F3-Expressing Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma Show Morphologic and Phenotypic OverlapNaoe Jimbo, Chiho Ohbayashi, Maiko Takeda, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 20, 2022
Local dose (biologically effective dose ≥180 Gy2) is an important predictor of biochemical recurrence in patients undergoing low-dose-rate brachytherapyNobumichi Tanaka, Yasushi Nakai, Isao Asakawa, et al.
Anticancer Research|December 29, 2018
Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel <i>KIF5B-ALK</i> Fusion OncokinaseNaoki Shimizu, Yusaku Akashi, Tomomi Fujii, et al.
Brachytherapy|February 7, 2018
Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer-A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitorNobumichi Tanaka, Kazumasa Torimoto, Isao Asakawa, et al.
Research and Reports in Urology|March 11, 2021
Effect of Prolonged Duration of Transrectal Ultrasound-Guided Biopsy of the Prostate and Pre-Procedure Anxiety on Pain in Patients without AnesthesiaYasushi Nakai, Nobumichi Tanaka, Toshihiko Matsubara, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 13, 2020
Coverage of the external prostatic region by the hybrid method compared with the conventional method of prostate low-dose-rate brachytherapy: A randomized controlled studyNobumichi Tanaka, Isao Asakawa, Yasushi Nakai, et al.
BMC Cancer|August 27, 2017
Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancerNobumichi Tanaka, Isao Asakawa, Yasushi Nakai, et al.
BMC Cancer|November 20, 2016
Keratin 19 as a key molecule in progression of human hepatocellular carcinomas through invasion and angiogenesisMasato Takano, Keiji Shimada, Tomomi Fujii, et al.
Pageof 16

Showing results (51-60 of 159) with videos related to

Sort By:
Pageof 16
Journal of Contemporary Brachytherapy|November 22, 2019
Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancerYasushi Nakai, Nobumichi Tanaka, Isao Asakawa, et al.
Histopathology|October 10, 2023
Implication of cytoplasmic p53 expression in pulmonary neuroendocrine carcinoma using next-generation sequencing analysisNaoe Jimbo, Chiho Ohbayashi, Tomomi Fujii, et al.
The American Journal of Surgical Pathology|October 31, 2023
POU2F3-Expressing Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma Show Morphologic and Phenotypic OverlapNaoe Jimbo, Chiho Ohbayashi, Maiko Takeda, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 20, 2022
Local dose (biologically effective dose ≥180 Gy2) is an important predictor of biochemical recurrence in patients undergoing low-dose-rate brachytherapyNobumichi Tanaka, Yasushi Nakai, Isao Asakawa, et al.
Anticancer Research|December 29, 2018
Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel <i>KIF5B-ALK</i> Fusion OncokinaseNaoki Shimizu, Yusaku Akashi, Tomomi Fujii, et al.
Brachytherapy|February 7, 2018
Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer-A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitorNobumichi Tanaka, Kazumasa Torimoto, Isao Asakawa, et al.
Research and Reports in Urology|March 11, 2021
Effect of Prolonged Duration of Transrectal Ultrasound-Guided Biopsy of the Prostate and Pre-Procedure Anxiety on Pain in Patients without AnesthesiaYasushi Nakai, Nobumichi Tanaka, Toshihiko Matsubara, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 13, 2020
Coverage of the external prostatic region by the hybrid method compared with the conventional method of prostate low-dose-rate brachytherapy: A randomized controlled studyNobumichi Tanaka, Isao Asakawa, Yasushi Nakai, et al.
BMC Cancer|August 27, 2017
Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancerNobumichi Tanaka, Isao Asakawa, Yasushi Nakai, et al.
BMC Cancer|November 20, 2016
Keratin 19 as a key molecule in progression of human hepatocellular carcinomas through invasion and angiogenesisMasato Takano, Keiji Shimada, Tomomi Fujii, et al.
Pageof 16